润都股份(002923.SZ)：氢氯噻嗪获得化学原料药上市申请批准通知书

Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the marketing application of hydrochlorothiazide, which enhances its product portfolio and strengthens its full industry chain layout [1]. Group 1 - The approved product, hydrochlorothiazide, is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and kidney stones [1]. - The approval of hydrochlorothiazide contributes to the diversification of the company's product offerings [1]. - This development is part of the company's strategy to improve its comprehensive industry chain [1].